Despite therapy with intravenous immunoglobulin (IVIG) plus infliximab, a monoclonal antibody against the pro- inflammatory cytokine tumor necrosis factor (TNF) ?, more than 25% of children with Kawasaki disease (KD), the most common cause of acquired heart disease in children, develop coronary artery abnormalities (CAA) with either dilated or aneurysmal coronary arteries. Once aneurysms have formed, the damage to the arterial wall is irreversible, and over time, stenoses and calcification may lead to ischemic complications. However, there is no recommended therapy to halt the progression of arterial wall damage and prevent aneurysm formation. Thus, the goal of our project is to test a new therapy to attenuate CAA and block progression of early injury to aneurysm formation. In KD, the IL-1 pathway is upregulated, as demonstrated by increased transcript abundance by microarray and by increased levels of pathway proteins in the plasma. In the Lactobacillus casei cell wall extract KD mouse model of coronary arteritis, the IL-1 receptor antagonist, anakinra, prevented the development of CAA, as did knocking out the IL-1 receptor. Given the role of the IL-1 pathway in KD-associated inflammation, blockade of IL-1 with anakinra is a logical therapy to attenuate CAA in KD. Treatment with anakinra has been well-tolerated and has coincided with a decrease in systemic inflammation and CAA in a small number of KD patients. However, despite its increasing off-label use, there are limited data in infants and young children. The proposed Phase I/IIa, dose escalation study will determine if anakinra in children at least 8 months to 17 years of age treated with IVIG and aspirin who have evidence of CAA by echocardiography is safe and well- tolerated (Specific Aim 1). Furthermore, this study will evaluate if anakinra has high bioavailability and whether its pharmacokinetics can be characterized by a one-compartment model using sparse sampling (Specific Aim 2). Lastly, this study will develop a pharmacodynamic biomarker-based model to find the proper dose of anakinra for a sustained anti-inflammatory effect in children with acute KD and CAAs. (Specific Aim3). Understanding the safety, PK, and proper dosing of anakinra to have a sustained anti-inflammatory effect are central to moving forward with a Phase III study and addressing the unmet clinical need of preventing formation or progression of aneurysms in KD.

National Institute of Health (NIH)
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZHD1-DSR-Z (50))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Diego
La Jolla
United States
Zip Code
Patras, Kathryn A; Nizet, Victor (2018) Group B Streptococcal Maternal Colonization and Neonatal Disease: Molecular Mechanisms and Preventative Approaches. Front Pediatr 6:27
Kumaraswamy, Monika; Do, Carter; Sakoulas, George et al. (2018) Listeria monocytogenes endocarditis: case report, review of the literature, and laboratory evaluation of potential novel antibiotic synergies. Int J Antimicrob Agents 51:468-478
Nikanjam, Mina; Capparelli, Edmund V; Lancet, Jeffrey E et al. (2018) Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment. Cancer Chemother Pharmacol 81:171-178
Nigam, Sanjay K (2018) The SLC22 Transporter Family: A Paradigm for the Impact of Drug Transporters on Metabolic Pathways, Signaling, and Disease. Annu Rev Pharmacol Toxicol 58:663-687
Momper, Jeremiah D; Nigam, Sanjay K (2018) Developmental regulation of kidney and liver solute carrier and ATP-binding cassette drug transporters and drug metabolizing enzymes: the role of remote organ communication. Expert Opin Drug Metab Toxicol 14:561-570
Nikanjam, Mina; Sun, Aida; Albers, Mark et al. (2018) Vincristine-associated Neuropathy With Antifungal Usage: A Kaiser Northern California Experience. J Pediatr Hematol Oncol 40:e273-e277
Lin, Swan; Nikanjam, Mina; Capparelli, Edmund V et al. (2018) Evaluation of Omeprazole Limited Sampling Strategies to Estimate Constitutive Cytochrome P450 2C19 Activity in Healthy Adults. Ther Drug Monit 40:754-758
Le, Jennifer; Poindexter, Brenda; Sullivan, Janice E et al. (2018) Comparative Analysis of Ampicillin Plasma and Dried Blood Spot Pharmacokinetics in Neonates. Ther Drug Monit 40:103-108
Kumaraswamy, Monika; Collignon, Sean; Do, Carter et al. (2018) Decontaminating surfaces with atomized disinfectants generated by a novel thickness-mode lithium niobate device. Appl Microbiol Biotechnol 102:6459-6467
Bush, Kevin T; Wu, Wei; Lun, Christina et al. (2017) The drug transporter OAT3 (SLC22A8) and endogenous metabolite communication via the gut-liver-kidney axis. J Biol Chem 292:15789-15803

Showing the most recent 10 out of 22 publications